BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32934722)

  • 1. Cyclin D1 overexpression enhances chemosensitivity to TPF chemotherapeutic agents via the caspase-3 pathway in oral cancer.
    Hu YJ; Sun WW; Zhao TC; Liu Y; Zhu DW; Wang LZ; Li J; Zhang CP; Zhang ZY; Zhong LP
    Oncol Lett; 2020 Nov; 20(5):154. PubMed ID: 32934722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease.
    Zhong LP; Zhu DW; William WN; Liu Y; Ma J; Yang CZ; Yang X; Wang LZ; Li J; Myers JN; Lee JJ; Zhang CP; Zhang ZY
    Mol Cancer Ther; 2013 Jun; 12(6):1112-21. PubMed ID: 23515614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma.
    Yang CZ; Ma J; Zhu DW; Liu Y; Montgomery B; Wang LZ; Li J; Zhang ZY; Zhang CP; Zhong LP
    Ann Oncol; 2014 Jun; 25(6):1215-22. PubMed ID: 24669014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normal BMI predicts the survival benefits of inductive docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced oral squamous cell carcinoma.
    Zhao TC; Liang SY; Ju WT; Liu Y; Tan YR; Zhu DW; Zhang CP; Zhang ZY; Zhong LP
    Clin Nutr; 2020 Sep; 39(9):2751-2758. PubMed ID: 31839432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma.
    Zhong LP; Zhang CP; Ren GX; Guo W; William WN; Hong CS; Sun J; Zhu HG; Tu WY; Li J; Cai YL; Yin QM; Wang LZ; Wang ZH; Hu YJ; Ji T; Yang WJ; Ye WM; Li J; He Y; Wang YA; Xu LQ; Zhuang Z; Lee JJ; Myers JN; Zhang ZY
    Oncotarget; 2015 Jul; 6(21):18707-14. PubMed ID: 26124084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased Annexin A1 expression enhances sensitivity to docetaxel, cisplatin and 5-fluorouracil combination induction chemotherapy in oral squamous cell carcinoma.
    Sun W; Zhao T; Aladelusi TO; Ju W; Zhang Z; Zhong L; Zhu D
    J Oral Pathol Med; 2021 Sep; 50(8):795-802. PubMed ID: 34157171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated growth differentiating factor 15 expression predicts long-term benefit of docetaxel, cisplatin and 5-fluorouracil induction chemotherapy in patients with oral cancer.
    Tang X; Hu YJ; Ju WT; Fu Y; Sun WW; Liu Y; Tan YR; Wang LZ; Li J; Tu YY; Zhang CP; Zhang ZY; Zhong LP
    Oncol Lett; 2018 May; 15(5):8118-8124. PubMed ID: 29731919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stathmin guides personalized therapy in oral squamous cell carcinoma.
    Ju WT; Ma HL; Zhao TC; Liang SY; Zhu DW; Wang LZ; Li J; Zhang ZY; Zhou G; Zhong LP
    Cancer Sci; 2020 Apr; 111(4):1303-1313. PubMed ID: 31994271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low Annexin A1 expression predicts benefit from induction chemotherapy in oral cancer patients with moderate or poor pathologic differentiation grade.
    Zhu DW; Liu Y; Yang X; Yang CZ; Ma J; Yang X; Qiao JK; Wang LZ; Li J; Zhang CP; Zhang ZY; Zhong LP
    BMC Cancer; 2013 Jun; 13():301. PubMed ID: 23786757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of sensitivity to cisplatin, docetaxel, and 5-fluorouracil chemoagents and potential erbB2 alternatives in oral cancer with growth differentiation factor 15 overexpression.
    Zhao TC; Zhou ZH; Ju WT; Liang SY; Tang X; Zhu DW; Zhang ZY; Zhong LP
    Cancer Sci; 2022 Feb; 113(2):478-488. PubMed ID: 34826159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phospholipase C gamma 1 is a potential prognostic biomarker for patients with locally advanced and resectable oral squamous cell carcinoma.
    Zhu D; Tan Y; Yang X; Qiao J; Yu C; Wang L; Li J; Zhang Z; Zhong L
    Int J Oral Maxillofac Surg; 2014 Dec; 43(12):1418-26. PubMed ID: 25085076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
    Janoray G; Pointreau Y; Garaud P; Chapet S; Alfonsi M; Sire C; Jadaud E; Calais G
    J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26681800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis.
    Teo M; Karakaya E; Young CA; Dyker KE; Coyle C; Sen M; Prestwich RJ
    Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):647-53. PubMed ID: 23948462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effect and mechanism of ANXA1 on TPF chemosensitivity in oral squamous cell carcinoma].
    Zhu DW; Sun WW; Zhao TC; Zhong LP; Zhang ZY
    Shanghai Kou Qiang Yi Xue; 2019 Jun; 28(3):225-230. PubMed ID: 31489406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
    Vermorken JB; Remenar E; van Herpen C; Gorlia T; Mesia R; Degardin M; Stewart JS; Jelic S; Betka J; Preiss JH; van den Weyngaert D; Awada A; Cupissol D; Kienzer HR; Rey A; Desaunois I; Bernier J; Lefebvre JL;
    N Engl J Med; 2007 Oct; 357(17):1695-704. PubMed ID: 17960012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of docetaxel, cisplatin, and 5-fluorouracil as an induction chemotherapy in oral squamous cell carcinoma in a tertiary hospital in Saudi Arabia.
    Alessa M; Alhifany AA; Almatrafi NA; Bahaj AS; Alkaf HH; Alharbi J; Almaghrabi MY; Alsubaie HM; Elkhatib H; Albadainah F; Abdelmonim S
    Saudi Pharm J; 2024 Jan; 32(1):101885. PubMed ID: 38077121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
    Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C
    Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of cyclin D1 expression by cyclin D1 shRNAs in human oral squamous cell carcinoma cells is associated with increased cisplatin chemosensitivity.
    Zhou X; Zhang Z; Yang X; Chen W; Zhang P
    Int J Cancer; 2009 Jan; 124(2):483-9. PubMed ID: 18942709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lactate dehydrogenase B is associated with the response to neoadjuvant chemotherapy in oral squamous cell carcinoma.
    Sun W; Zhang X; Ding X; Li H; Geng M; Xie Z; Wu H; Huang M
    PLoS One; 2015; 10(5):e0125976. PubMed ID: 25973606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
    Kim R; Hahn S; Shin J; Ock CY; Kim M; Keam B; Kim TM; Kim DW; Heo DS
    Cancer Res Treat; 2016 Jul; 48(3):907-16. PubMed ID: 26582394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.